0MH6

Ipsen SA

Healthcare · EUR · EPA

IPNT212

Price

€156.9

-1.63%

Cap

€7.63B

Earnings

30d Trend

-4.4%

0MH6
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityModerate

31% annualised over 90 days

BRAIN47 SIGNAL

0
MODERATE
Risk Level43
Quality28
Momentum88
Technical59
Fundamentals41

Raw weighted: 53×Macro 0.99 (1%)=52

RISK

43/100
90d Volatility
30.5%Moderate
ATR %
2.5%Normal
Max Drawdown (1Y)
-11.8%Resilient

QUALITY

28/100
Piotroski F-Score
3/9Weak
Margin Stability
CV 87.6%Volatile

MOMENTUM

88/100
12-1M Momentum
+58.7%Strong uptrend
6-1M Momentum
+29.7%Positive
1M Return
-4.4%Recent pullback

TECHNICAL

59/100
RSI (14)
40.2Neutral
Price vs SMA200
+14.2%Bullish trend
MACD
-0.87Bearish momentum
Bollinger Band
9%Near lower band
SMA Cross
Death CrossDeath Cross
Trend Quality (KER)
0.147Noisy/choppy

FUNDAMENTALS

41/100
EV/EBIT
22.1Fair
P/S
3.5Fair
Shareholder Yield
0.0%Low

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months38
3-12 months67
1-5+ years47

6-9 month opportunity — emerging trend

BRAIN47'S ASSESSMENT

I rate Ipsen SA at 52/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 88/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.

PAST PERFORMANCE

1 MONTH

-4.4%

3 MONTHS

-5.6%

12 MONTHS

+54.4%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

6-9 month opportunity — emerging trend. Momentum (88) and Technical (59) are the primary strengths. I note that quality is the weakest area at 28/100 — this warrants monitoring. Historical volatility is moderate at 31%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.

growthScore: 52/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.